News & Analysis as of

Patents Bristol-Myers Squibb Intellectual Property Litigation

Goodwin

Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 and Anti-CTLA-4 Antibody Combination Method of Treatment...

Goodwin on

On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”). The claims of all three patents are...more

1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide